Australia's most trusted
source of pharma news
Wednesday, 04 February 2026
Posted 3 February 2026 PM
A $200 million PBS market has been slashed in half, but at the sponsor's request.
At the beginning of December the PBS list price for Takeda's Vyvanse fell by around half, four months before it was due for a smaller 10-year anniversary price reduction and despite the drug seemingly being under patent protection until at least 2028.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.